| Institution | PI Name | Title |
|---|
| Apath, LLC | Paul Olivo | Therapeutics for Ebola virus |
| Arizona State University | Bertram Jacobs | Development of a post-exposure vaccine for smallpox |
| Children's Hospital and Research Center at Oakland | Donald Reason | Human monoclonal panel mimicking anthrax immune globulin |
| Maxthera, Inc. | Ania Knap | Broad Spectrum Agents Against Cat A Bacterial Pathogens |
| Nanotherapeutics, Inc. | James Talton | Inhaled Aminoglycoside Formulafor Plague and Tularemia |
| Novobiotic Pharmaceuticals, LLC | Losee Ling | Novel Antibiotics from Unculturable Actinomycetes |
| New York University School of Medicine | Martin Blaser
| Development of furanones for treatment of anthrax |
| Oncovir, Inc. | Andres Salazar | Poly-ICLC Prophylaxis Treatment of Ebola Virus Infection |
| Scripps Research Institute | Kim Janda | High-Throughput Identification of BoNT Inhibitors |
| University of Chicago | Wei-Jen Tang | Intervention against anthrax edema factor (EF) |
| Veritas, Inc. | George Oyler | High Throughput Screens for Botulinum Toxin Therapeutics |
| Veterans Medical Research Foundation, San Diego | Karl Hostetler | Analogs of HPMPA for Treatment of Smallpox |